Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease.
Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease. Curr Med Res Opin. 2018 Jul 11;:1-15 Authors: Kirienko A, Radak D, Maggioli A Abstract AIM: To investigate the clinical efficacy of micronized purified flavonoid fraction (MPFF) 1000 mg given as a single 1000 mg tablet once daily in patients suffering from chronic venous disease (CVD) versus MPFF 500 mg twice daily. METHODS: In an international, randomized, double-blind, parallel-group study, patients classified C0s to C4 according to Clinical Etiological Anatomic Pathophysiologic [CEAP] classification and with leg pain graded as superior to 4 cm on a 10-cm visual analog scale (VAS), were treated for 8 weeks with either MPFF 1000 mg once daily or MPFF 500 mg twice daily. The present post-hoc analysis focuses on the effect of treatment over time in patients randomized to the MPFF 1000 mg group. Leg pain was assessed at each follow-up visit by VAS. VAS scores over time were compared between in each visit using paired Student t tests. RESULTS: 87 patients over 174 were randomized to the MPFF 1000 mg group. Mean age (± SD) was 49.1±12.2 years, most of the patients were female (81.6%), the main CEAP classes of the most affected leg were C1 (20.7%), C2 (39.1%), C3 (33.33%) and the mean duration of CVD was 14.6±10.9 years. Patients wit...
In this study, we retrospectively compared physical and psychological factors in patients with acute and chronic orofacial pain. We analyzed data from 854 patients presenting to the Orofacial Pain Center, Department of Dental Anesthesiology, Tokyo Dental College, Suidobashi Hospital between April 2010 and March 2014. We categorized patients into the acute group if their condition had persisted
The Prostate, EarlyView.
This report describes a case of ischemic colitis (IC) caused by PV and includes a review of the relevant literature. The patient was a 59-year-old male with a history of PV who presented with abdominal pain and hematochezia. Colonoscopy and histopathological examination results indicated suspected ischemic bowel disease. Following experimental anticoagulant therapy for 7 days, the patient no longer experienced abdominal pain and hematochezia had resolved. Colonoscopy review showed no obvious anomalies 1 month later. These data demonstrated that PV is an uncommon cause of IC. PMID: 30233723 [PubMed]
ConclusionsThis study has elucidated the genome-wide effects of several adaptogenic herbal extracts in brain cells culture. These data highlight the consistent activation of ASRSPs by adaptogens in T98G neuroglia cells. The extracts affected many genes playing key roles in modulation of adaptive homeostasis, indicating their ability to modify gene expression to prevent stress-induced and aging-related disorders. Overall, this study provides a comprehensive look at the molecular mechanisms by which adaptogens exerts stress-protective effects.Graphycal abstract
Publication date: October 2018Source: The Annals of Thoracic Surgery, Volume 106, Issue 4Author(s): Donna May Kimmaliardjuk, Carole Dennie, Sean Dickie, Eric C. Belanger, Fraser RubensA 29-year-old man with chronic pulmonary emboli presented to the hospital with progressive pleuritic chest pain. He was in acute right ventricular failure and received intrapulmonary arterial tissue plasminogen activator. Massive hemoptysis developed, requiring emergent thromboendarterectomy. A clot was visualized in the main left pulmonary artery that had formed a bronchovascular fistula into the left upper lobe bronchus. Pathology of the cl...
(University of Gothenburg) The picture is becoming clearer regarding the chronic oral pain condition known as Burning Mouth Syndrome, or BMS, which mainly affects women who are middle-aged and older. In a dissertation at Sahlgrenska Academy, additional steps are being taken toward better diagnosis and treatment.
DiscussionThe findings are generally consistent with a BIS-BAS 2-factor model of chronic pain, suggesting BIS and BAS activity as potential targets for chronic pain treatment.
Date: Tuesday, 10 30, 2018; Speaker: Dr. John Heiss, NINDS; Dr. Magdalena Naylor, NCCIH; Building: Building 10 (Clinical Center); Lipsett Auditorium ; CME Credit
Chronic abdominal pain due to anterior cutaneous nerve entrapment syndrome may require surgery to provide long-term pain relief in up to 70% of patients. Factors predicting outcome after an anterior neurectomy are unknown. The aim of the study is to identify factors associated with treatment failure to possibly allow for optimizing patient counselling and selection.
Randomised controlled trials (RCTs) are the cornerstone of evidence-based interventions both for chronic pain and medicine more generally. In particular, double-blind placebo-controlled RCTs have been heavily relied upon to determine treatment efficacy and safety of chronic pain interventions. Hundreds of double-blind placebo-controlled RCTs are run each year worldwide to test various interventions for chronic pain, with hundreds of thousands of people with chronic pain participating in these trials.